Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBIT (2020 - 2025)

Silence Therapeutics' EBIT history spans 6 years, with the latest figure at $56.5 million for Q4 2025.

  • On a quarterly basis, EBIT rose 18.0% to $56.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$22.2 million, a 118.44% decrease, with the full-year FY2025 number at -$22.2 million, down 99.26% from a year prior.
  • EBIT hit $56.5 million in Q4 2025 for Silence Therapeutics, up from -$26.2 million in the prior quarter.
  • Over the last five years, EBIT for SLN hit a ceiling of $56.5 million in Q4 2025 and a floor of -$16934.5 billion in Q3 2021.
  • Historically, EBIT has averaged -$846.7 billion across 5 years, with a median of -$16.1 million in 2022.
  • Biggest five-year swings in EBIT: plummeted 137149027196.87% in 2021 and later surged 389.9% in 2024.
  • Tracing SLN's EBIT over 5 years: stood at -$15.2 million in 2021, then rose by 15.32% to -$12.9 million in 2022, then decreased by 28.39% to -$16.5 million in 2023, then surged by 389.9% to $47.9 million in 2024, then increased by 18.0% to $56.5 million in 2025.
  • Business Quant data shows EBIT for SLN at $56.5 million in Q4 2025, -$26.2 million in Q3 2025, and -$24.0 million in Q2 2025.